Patents by Inventor Masatomo Kato

Masatomo Kato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8563551
    Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 22, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Patent number: 8551991
    Abstract: An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R2 represents a halogen, an alkyl, hydroxyl or alkoxy group, or the like; q represents 0 to 2; R3 represents hydrogen, an alkyl, alkenyl, alkylcarbonyl or arylcarbonyl group, or the like; R4 and R5 independently represent hydrogen, a halogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; R6 represents hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, or the like; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; and X represents O or S.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: October 8, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Masato Nagatsuka, Sachiko Kobayashi
  • Patent number: 8440660
    Abstract: A method for treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 14, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Patent number: 8426406
    Abstract: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: April 23, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Mamoru Matsuda, Toshiyuki Mori, Kenji Imoto, Atsuyoshi Dota
  • Patent number: 8420635
    Abstract: A method of preventing or treating a glucocorticoid receptor-related disease involving administering a therapeutically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: April 16, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Masato Nagatsuka, Sachiko Kobayashi, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Tomoko Oda
  • Patent number: 8193187
    Abstract: The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, a lower alkyl group and the like; R3 represents a hydrogen atom, a lower alkyl group and the like; R4 and R5 represent a hydrogen atom, a lower alkyl group and the like; R6 represents a hydrogen atom, a lower alkyl group and the like; R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR8 and the like; R8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR9, OCO or OSO2; R9 represents a hydrogen atom, a lower alkyl group and the like respectively.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: June 5, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Masato Nagatsuka, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20120129866
    Abstract: A method for preventing or treating a metabolic disorder, an inflammatory disease, an autoimmune disease, an allergic disease, a central nervous system disease, a cardiovascular disease, a homeostasis-related disease or glaucoma, involving administering a compound or a salt thereof, the compound having the following formula (1) wherein R1 represents alkyl, cycloalkyl, aryl, heterocyclic or aralkyl; R7 represents cycloalkyl, aryl or heterocyclic; W represents oxygen or NR8, Y represents alkylene, Z represents oxygen, sulfur, OCO or NR9; R2, R3, R4, R6, R8 and R9 represent hydrogen or alkyl.
    Type: Application
    Filed: February 2, 2012
    Publication date: May 24, 2012
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Masato Nagatsuka, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20110275620
    Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 10, 2011
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20110275632
    Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 10, 2011
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Mamoru MATSUDA, Masato NAGATSUKA, Toshiyuki MORI, Sachiko KOBAYASHI, Masatomo KATO, Miwa TAKAI
  • Publication number: 20110263589
    Abstract: A method of preventing or treating a glucocorticoid receptor-related disease involving administering a therapeutically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 28, 2011
    Publication date: October 27, 2011
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Masato Nagatsuka, Sachiko Kobayashi, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Tomoko Oda
  • Publication number: 20110263600
    Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 27, 2011
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Patent number: 8017775
    Abstract: An object of the present invention is to study synthesis of a novel 1,2-dihydroquinoline derivative and to find a pharmacological action of the derivative. A compound represented by the general formula (1) or a salt thereof is effective in the treatment of a glucocorticoid receptor-related disease. In the formula, the ring X represents a benzene ring or a pyridine ring; R1 represents a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, an amino group or the like; p represents an integer of 0 to 5; R2 represents a halogen atom, an alkyl group, a hydroxy group or the like; q represents an integer of 0 to 2; R3 represents a hydrogen atom, an alkyl group, an alkenyl group or the like; R4 and R5 represent a hydrogen atom or the like; R6 represents a hydrogen atom or the like; A represents an alkylene group or the like; and R7 represents OR8, NR8R9, SR8, S(O)R8 or S(O)2R8, wherein R8 represents an aryl group, a heterocyclic group or the like and R9 represents a hydrogen atom or the like.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: September 13, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Masato Nagatsuka, Sachiko Kobayashi, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Tomoko Oda
  • Patent number: 8008498
    Abstract: The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represents a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a nitro group or a cyano group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; and P represents 0, 1, 2 or 3.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 30, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Patent number: 8008497
    Abstract: The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a nitro group or a cyano group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a benzene ring or a heterocyclic ring; and P represents 0, 1, 2 or 3.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 30, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Patent number: 8008496
    Abstract: The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 30, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20110166151
    Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).
    Type: Application
    Filed: September 11, 2009
    Publication date: July 7, 2011
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Kenji Oki, Mamoru Matsuda, Toshiyuki Mori
  • Publication number: 20110118260
    Abstract: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.
    Type: Application
    Filed: May 12, 2009
    Publication date: May 19, 2011
    Applicant: SANTEN PHARMACEUTICAL CO.,LTD.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Mamoru Matsuda, Toshiyuki Mori, Kenji Imoto, Atsuyoshi Dota
  • Publication number: 20100137307
    Abstract: The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, a lower alkyl group and the like; R3 represents a hydrogen atom, a lower alkyl group and the like; R4 and R5 represent a hydrogen atom, a lower alkyl group and the like; R6 represents a hydrogen atom, a lower alkyl group and the like; R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR8 and the like; R8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR9, OCO or OSO2; R9 represents a hydrogen atom, a lower alkyl group and the like respectively.
    Type: Application
    Filed: May 29, 2008
    Publication date: June 3, 2010
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Masato Nagatsuka, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20100056504
    Abstract: The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group; R6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group; X represents —C(O)—, —C(O)NR8—, —S(O)2— and the like; R7 and/or R8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
    Type: Application
    Filed: November 14, 2007
    Publication date: March 4, 2010
    Inventors: Mamoru Matsuda, Masato Nagatsuka, Toshiyuki Mori, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
  • Publication number: 20090326009
    Abstract: An object of the present invention is to study synthesis of a novel 1,2-dihydroquinoline derivative and to find a pharmacological action of the derivative. A compound represented by the general formula (1) or a salt thereof is effective in the treatment of a glucocorticoid receptor-related disease. In the formula, the ring X represents a benzene ring or a pyridine ring; R1 represents a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, an amino group or the like; p represents an integer of 0 to 5; R2 represents a halogen atom, an alkyl group, a hydroxy group or the like; q represents an integer of 0 to 2; R3 represents a hydrogen atom, an alkyl group, an alkenyl group or the like; R4 and R5 represent a hydrogen atom or the like; R6 represents a hydrogen atom or the like; A represents an alkylene group or the like; and R7 represents OR8, NR8R9, SR8, S(O)R8 or S(O)2R8, wherein R8 represents an aryl group, a heterocyclic group or the like and R9 represents a hydrogen atom or the like.
    Type: Application
    Filed: September 14, 2006
    Publication date: December 31, 2009
    Applicant: Santen Pharmaceutical Co.,
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Masato Nagatsuka, Sachiko Kobayashi, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Tomoko Oda